FierceBiotechFierceBioResearcherFierceVaccinesFiercePharma   FierceHealthcare

SPOTLIGHT: Avastin leaves ASCO ahead of Erbitux


Shares of Genentech have been buoyed by news from ASCO that Avastin will likely be preferred to Erbitux for treating lung cancer. Avastin offers an extra month of average survival time compared to Erbitux. Report

More stories about Erbitux   Avastin   Genentech   ASCO   lung cancer  

Comments

Post new comment

The content of this field is kept private and will not be shown publicly.

More information about formatting options

What is 2 + 91?
To combat spam, please solve the math question above.